Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 11.08%24.07B | 12.29%118.51B | 14.23%39.63B | 11.95%30.15B | 14.61%27.07B | 6.72%21.67B | -6.53%105.54B | -1.37%34.69B | -2.93%26.93B | -10.62%23.62B |
Cost of revenue | 8.82%16.78B | 11.82%79.03B | 13.16%23.77B | 12.93%20.83B | 15.71%19.02B | 4.22%15.42B | -4.68%70.68B | -2.40%21.01B | -2.78%18.44B | -6.01%16.44B |
Gross profit | 16.64%7.29B | 13.24%39.47B | 15.87%15.86B | 9.82%9.32B | 12.10%8.05B | 13.43%6.25B | -10.07%34.86B | 0.26%13.68B | -3.25%8.48B | -19.65%7.18B |
Operating expense | 6.22%6.78B | 7.04%27.8B | 11.01%7.66B | 6.80%7.34B | 4.50%6.42B | 5.38%6.39B | -0.57%25.98B | -9.15%6.9B | 0.76%6.87B | 5.52%6.14B |
Staff costs | ---- | 3.95%15.51B | ---- | ---- | ---- | ---- | 0.57%14.92B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | 7.51%2.08B | ---- | ---- | ---- | ---- | 3.54%1.93B | ---- | ---- | ---- |
-General and administrative expense | ---- | 7.51%2.08B | ---- | ---- | ---- | ---- | 3.54%1.93B | ---- | ---- | ---- |
Research and development costs | ---- | 3.20%2.42B | ---- | ---- | ---- | ---- | -5.60%2.35B | ---- | ---- | ---- |
Depreciation and amortization | ---- | 6.87%1.04B | ---- | ---- | ---- | ---- | 0.83%975M | ---- | ---- | ---- |
-Depreciation | ---- | 6.99%1.03B | ---- | ---- | ---- | ---- | 0.31%959M | ---- | ---- | ---- |
-Amortization | ---- | 0.00%16M | ---- | ---- | ---- | ---- | 45.45%16M | ---- | ---- | ---- |
Rent and land expenses | ---- | 10.14%1.76B | ---- | ---- | ---- | ---- | 4.31%1.6B | ---- | ---- | ---- |
Other operating expenses | ---- | 18.79%5B | ---- | ---- | ---- | ---- | -5.27%4.21B | ---- | ---- | ---- |
Operating profit | 472.79%507M | 31.35%11.67B | 20.82%8.19B | 22.69%1.98B | 57.02%1.63B | 75.27%-136M | -29.71%8.88B | 12.08%6.78B | -17.28%1.61B | -66.63%1.04B |
Net non-operating interest income (expenses) | 50.00%-2M | 0 | 20.00%6M | -300.00%-2M | 0 | -500.00%-4M | -23.08%10M | -37.50%5M | -50.00%1M | 200.00%3M |
Non-operating interest income | --2M | -22.73%17M | 11.11%10M | -50.00%3M | -20.00%4M | --0 | 0.00%22M | -18.18%9M | 50.00%6M | 25.00%5M |
Non-operating interest expense | 0.00%4M | 41.67%17M | 0.00%4M | 0.00%5M | 100.00%4M | 300.00%4M | 33.33%12M | 33.33%4M | 150.00%5M | -33.33%2M |
Net investment income | 16.18%79M | 13.64%125M | -39.47%23M | 0.00%22M | 1,100.00%12M | 38.78%68M | 66.67%110M | 100.00%38M | -18.52%22M | 116.67%1M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -59.70%54M | -46.53%54M | 0 | 930.77%134M | 676.92%101M | -5M | 0 | |||
Income from associates and other participating interests | -44.62%36M | 16.94%352M | 21.26%154M | -24.42%65M | 94.29%68M | 22.64%65M | 5.24%301M | 28.28%127M | -22.52%86M | 2.94%35M |
Special income (charges) | 0 | -103.11%-21M | -5.00%-21M | -100.25%-2M | 97.59%-2M | 130.77%4M | 22,433.33%676M | -300.00%-20M | 39,700.00%792M | -692.86%-83M |
Less:Other special charges | ---- | 103.11%21M | ---- | ---- | -97.59%2M | -130.77%-4M | -2,314.29%-676M | 200.00%20M | -39,700.00%-792M | 692.86%83M |
Other non-operating income (expenses) | -6.45%29M | -4.30%89M | 90.00%38M | -71.88%9M | -42.11%11M | 40.91%31M | -34.51%93M | 150.00%20M | 268.42%32M | -83.33%19M |
Income before tax | 2,134.48%648M | 20.18%12.26B | 19.78%8.44B | -18.50%2.07B | 69.75%1.72B | 107.29%29M | -22.43%10.2B | 13.96%7.05B | 22.65%2.54B | -69.02%1.02B |
Income tax | 346.27%299M | 20.62%3.86B | 18.21%2.59B | -8.18%662M | 63.91%536M | 255.81%67M | -17.78%3.2B | 27.68%2.19B | 17.62%721M | -67.53%327M |
Net income | 1,043.24%349M | 19.98%8.41B | 20.47%5.85B | -22.55%1.41B | 72.63%1.19B | 89.55%-37M | -24.39%7.01B | 8.68%4.86B | 24.78%1.82B | -69.74%687M |
Net income continuous operations | 1,018.42%349M | 19.98%8.41B | 20.49%5.85B | -22.59%1.41B | 72.53%1.19B | 89.30%-38M | -24.38%7.01B | 8.68%4.86B | 24.76%1.82B | -69.68%688M |
Noncontrolling interests | 37.14%-22M | -1,085.71%-166M | -331.25%-74M | -277.78%-48M | 75.68%-9M | 2.78%-35M | 83.33%-14M | 184.21%32M | 280.00%27M | -15.63%-37M |
Net income attributable to the company | 18,650.00%371M | 22.10%8.57B | 22.80%5.92B | -18.69%1.46B | 65.06%1.2B | 99.37%-2M | -24.91%7.02B | 7.06%4.82B | 21.74%1.79B | -68.55%724M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 18,650.00%371M | 22.10%8.57B | 22.80%5.92B | -18.69%1.46B | 65.06%1.2B | 99.37%-2M | -24.91%7.02B | 7.06%4.82B | 21.74%1.79B | -68.55%724M |
Gross dividend payment | ||||||||||
Basic earnings per share | 15,700.00%6.24 | 22.06%142.1 | 22.76%98.18 | -18.72%24.14 | 64.89%19.82 | 99.24%-0.04 | -24.92%116.42 | 7.04%79.98 | 21.67%29.7 | -68.51%12.02 |
Diluted earnings per share | 15,700.00%6.24 | 22.06%142.1 | 22.79%98.1786 | -18.72%24.14 | 65.01%19.8069 | 99.24%-0.04 | -24.92%116.42 | 7.03%79.9569 | 21.67%29.7 | -68.55%12.0037 |
Dividend per share | 0 | 32.50%53 | 50.00%30 | 0 | 15.00%23 | 0 | 11.11%40 | 11.11%20 | 0 | 11.11%20 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |